Evaluation of Plasma Phosphorylated Tau217 for Differentiating Alzheimer's Disease
In our current study, plasma p-tau217 levels did not differentiate AD with DLB, AD with vascular pathology, or AD with CAA cases from the AD group, though they could differentiate AD from cases with mixed pathologies, TDP-43 only, synuclein only, and tau-only pathology. This suggests co-existing AD pathology, making their p-tau measurements similar to the AD group. Further studies with autopsy-defined samples will be needed to clarify the role of plasma p-tau217 in these groups.
Authors
- Mary Joy Encarnacion (ORCID: https://orcid.org/0000-0002-2909-1247)
- Anna Mammel (ORCID: https://orcid.org/0000-0003-4271-8726)
- Ian R. Mackenzie (ORCID: https://orcid.org/0000-0003-3875-2972)
- Hans Frykman (ORCID: https://orcid.org/0000-0002-6863-5614)
- Donald Biehl
- Kelsey Hallett
- Ali Mousavi
- Veronica Hirsch‐Reinshagen
- Pankaj Kumar
- Ging‐Yuek Robin Hsiung
- Pradip Gil
Institutions
- University of British Columbia (CA)
- Institute of Neuroimmunology of the Slovak Academy of Sciences (SK)
- Western Washington University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_103744
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00